Versant Ventures, Eli Lilly and other investors backed Seawolf Therapeutics with $100 million to develop DNA-based therapeutics delivered without viral vectors. Seawolf says its TRIDENT platform uses lipid nanoparticles to package engineered DNA and support delivery into the nucleus, aiming for potent, durable expression with the ability to redose. Sanofi also entered a partnership with the startup, structured as an exclusive, multi-target license agreement focused on therapies for bleeding disorders and additional undisclosed indications. The combination of big-pharma capital and a strategic partner underscores investor appetite for gene delivery approaches that reduce viral constraints. For the field, the critical test will be whether non-viral delivery can maintain robust transfection and expression across relevant tissues while meeting safety requirements that have limited progress for other redosable gene approaches.
Get the Daily Brief